[
  {
    "id": "84314f92-9db4-4d0e-9f27-549a801541b0",
    "medication_name": "Ozempic",
    "generic_name": "semaglutide",
    "manufacturer": "Novo Nordisk",
    "drug_class": "GLP-1 Receptor Agonist",
    "indication": "Type 2 diabetes, weight management",
    "dosage_forms": "Pre-filled injection pen",
    "common_dosages": "0.25mg, 0.5mg, 1mg, 2mg weekly",
    "typical_retail_price": "$800-$1000/month",
    "fda_approval_date": null,
    "description": "Once-weekly injection that helps control blood sugar and promotes weight loss.",
    "side_effects": "Nausea, vomiting, diarrhea",
    "warnings": "Risk of thyroid tumors, pancreatitis",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  },
  {
    "id": "b6184bdd-c8c6-4ad2-9bd5-2faa85e75370",
    "medication_name": "Mounjaro",
    "generic_name": "tirzepatide",
    "manufacturer": "Eli Lilly",
    "drug_class": "GLP-1/GIP Receptor Agonist",
    "indication": "Type 2 diabetes",
    "dosage_forms": "Pre-filled injection pen",
    "common_dosages": "2.5mg-15mg weekly",
    "typical_retail_price": "$900-$1100/month",
    "fda_approval_date": null,
    "description": "Dual-action injectable medication for type 2 diabetes.",
    "side_effects": "Nausea, diarrhea",
    "warnings": "Risk of thyroid tumors, pancreatitis",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  },
  {
    "id": "27cbc0db-a4bb-4d0c-a4b7-28937499a6dc",
    "medication_name": "Trulicity",
    "generic_name": "dulaglutide",
    "manufacturer": "Eli Lilly",
    "drug_class": "GLP-1 Receptor Agonist",
    "indication": "Type 2 diabetes",
    "dosage_forms": "Pre-filled injection pen",
    "common_dosages": "0.75mg-4.5mg weekly",
    "typical_retail_price": "$750-$900/month",
    "fda_approval_date": null,
    "description": "Once-weekly GLP-1 injection for type 2 diabetes.",
    "side_effects": "Nausea, diarrhea",
    "warnings": "Risk of thyroid tumors",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  },
  {
    "id": "cd054e26-9d50-4e38-9a25-b999dcd046ee",
    "medication_name": "Jardiance",
    "generic_name": "empagliflozin",
    "manufacturer": "Boehringer Ingelheim",
    "drug_class": "SGLT2 Inhibitor",
    "indication": "Type 2 diabetes, heart failure",
    "dosage_forms": "Tablet",
    "common_dosages": "10mg, 25mg daily",
    "typical_retail_price": "$500-$650/month",
    "fda_approval_date": null,
    "description": "Lowers blood sugar by helping kidneys remove glucose.",
    "side_effects": "UTIs, increased urination",
    "warnings": "Risk of ketoacidosis",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  },
  {
    "id": "0083ab8a-831a-42ac-9ba6-ac246495afca",
    "medication_name": "Farxiga",
    "generic_name": "dapagliflozin",
    "manufacturer": "AstraZeneca",
    "drug_class": "SGLT2 Inhibitor",
    "indication": "Type 2 diabetes, heart failure",
    "dosage_forms": "Tablet",
    "common_dosages": "5mg, 10mg daily",
    "typical_retail_price": "$500-$650/month",
    "fda_approval_date": null,
    "description": "SGLT2 inhibitor for diabetes and heart failure.",
    "side_effects": "Yeast infections, UTIs",
    "warnings": "Risk of ketoacidosis",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  },
  {
    "id": "803430a0-9a67-4c07-9dee-e860da7adaad",
    "medication_name": "Lantus",
    "generic_name": "insulin glargine",
    "manufacturer": "Sanofi",
    "drug_class": "Long-acting Insulin",
    "indication": "Type 1 and Type 2 diabetes",
    "dosage_forms": "Vial, pen",
    "common_dosages": "Individualized",
    "typical_retail_price": "$250-$400/month",
    "fda_approval_date": null,
    "description": "Long-acting basal insulin for 24-hour control.",
    "side_effects": "Low blood sugar, weight gain",
    "warnings": "Risk of severe hypoglycemia",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  },
  {
    "id": "944246d1-a55d-4477-88f1-f93e92692e0e",
    "medication_name": "Humalog",
    "generic_name": "insulin lispro",
    "manufacturer": "Eli Lilly",
    "drug_class": "Rapid-acting Insulin",
    "indication": "Type 1 and Type 2 diabetes",
    "dosage_forms": "Vial, pen",
    "common_dosages": "With meals",
    "typical_retail_price": "$250-$400/month",
    "fda_approval_date": null,
    "description": "Fast-acting mealtime insulin.",
    "side_effects": "Low blood sugar",
    "warnings": "Risk of severe hypoglycemia",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  },
  {
    "id": "2008c6d8-6e12-4cc3-af23-ec602c7007cc",
    "medication_name": "Humira",
    "generic_name": "adalimumab",
    "manufacturer": "AbbVie",
    "drug_class": "TNF Blocker",
    "indication": "Rheumatoid arthritis, psoriasis",
    "dosage_forms": "Injection",
    "common_dosages": "40mg every 2 weeks",
    "typical_retail_price": "$5000-$6000/month",
    "fda_approval_date": null,
    "description": "Biologic that blocks TNF to reduce inflammation.",
    "side_effects": "Infections, headache",
    "warnings": "Risk of serious infections",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  },
  {
    "id": "344e1a72-1e27-4cb8-9973-5c5fe4304869",
    "medication_name": "Enbrel",
    "generic_name": "etanercept",
    "manufacturer": "Amgen",
    "drug_class": "TNF Blocker",
    "indication": "Rheumatoid arthritis",
    "dosage_forms": "Injection",
    "common_dosages": "50mg weekly",
    "typical_retail_price": "$5000-$6000/month",
    "fda_approval_date": null,
    "description": "TNF blocker for autoimmune diseases.",
    "side_effects": "Infections, headache",
    "warnings": "Risk of serious infections",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  },
  {
    "id": "850bb107-924d-4aa0-959a-258c86622cd6",
    "medication_name": "Stelara",
    "generic_name": "ustekinumab",
    "manufacturer": "Janssen",
    "drug_class": "IL-12/23 Blocker",
    "indication": "Psoriasis, Crohns disease",
    "dosage_forms": "Injection, IV",
    "common_dosages": "45mg, 90mg q12w",
    "typical_retail_price": "$20000-$25000/year",
    "fda_approval_date": null,
    "description": "Biologic blocking IL-12 and IL-23.",
    "side_effects": "Infections, headache",
    "warnings": "Risk of serious infections",
    "active": true,
    "created_at": "2025-10-18T10:46:52.707371+00:00",
    "updated_at": "2025-10-18T10:46:52.707371+00:00"
  }
]